These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Cella D Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for breast cancer. Nielsen DL; Andersson M; Andersen JL; Kamby C Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic advances in women's cancers. Carroll AR; Coleman RL; Sood AK Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib re-challenge in advanced renal-cell carcinoma. Porta C; Paglino C; Grünwald V Br J Cancer; 2014 Sep; 111(6):1047-53. PubMed ID: 24800947 [TBL] [Abstract][Full Text] [Related]
10. SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival. Nuijten M; Mickisch G Br J Cancer; 2010 Jan; 102(1):232-3; author reply 234-5. PubMed ID: 20051962 [No Abstract] [Full Text] [Related]
11. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Ballini JP; Lovisa B; van den Bergh H; Griffioen AW J Cell Mol Med; 2012 Jul; 16(7):1553-62. PubMed ID: 21880113 [TBL] [Abstract][Full Text] [Related]
12. Updates on novel therapies for metastatic renal cell carcinoma. Courtney KD; Choueiri TK Ther Adv Med Oncol; 2010 May; 2(3):209-19. PubMed ID: 21789135 [TBL] [Abstract][Full Text] [Related]
13. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Bukowski RM Cancer Manag Res; 2010 Mar; 2():83-96. PubMed ID: 21188099 [TBL] [Abstract][Full Text] [Related]
14. Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise. Pooleri GK; Nair TB; Sanjeevan KV; Thomas A Indian J Surg Oncol; 2012 Jun; 3(2):114-9. PubMed ID: 23730100 [TBL] [Abstract][Full Text] [Related]
16. Biostatistics of VHL-Gene Transfection in the Health Informatics Analysis of Renal Cell Carcinoma. Gong Y; Wang D; Wang W Comput Math Methods Med; 2022; 2022():5297580. PubMed ID: 35035522 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of chemokine receptor lymphotactin receptor 1 has prognostic value in clear cell renal cell carcinoma. Chang X; Cao Y; Fu WL; Tang XF; Wang YL; Lv YF; Guo QN Mol Genet Genomic Med; 2021 Jan; 9(1):e1551. PubMed ID: 33377624 [TBL] [Abstract][Full Text] [Related]
18. Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome. Bhattacharyya R; Ha MJ; Liu Q; Akbani R; Liang H; Baladandayuthapani V JCO Clin Cancer Inform; 2020 May; 4():399-411. PubMed ID: 32374631 [TBL] [Abstract][Full Text] [Related]
19. Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo. Takai T; Tsujino T; Yoshikawa Y; Inamoto T; Sugito N; Kuranaga Y; Heishima K; Soga T; Hayashi K; Miyata K; Kataoka K; Azuma H; Akao Y Mol Ther; 2019 May; 27(5):1017-1027. PubMed ID: 30930112 [TBL] [Abstract][Full Text] [Related]
20. Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma. Patel UJ; May M J Adv Pract Oncol; 2017; 8(7):757-764. PubMed ID: 30333938 [No Abstract] [Full Text] [Related] [Next] [New Search]